Sensex Today | Stock Market LIVE Updates Wednesday: The GIFT Nifty indicated a negative open for the Nifty50 index. Most Asian markets advanced, tracking overnight gains on Wall Street
The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.
Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.
Dr Reddy's informed stock exchanges that certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient used in the product.
Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.
Glenmark Pharma stock advanced over 2% in Monday's intra-day trade, after the company's US arm announced the launch of Olanzapine single-dose vial.
In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise in the Nifty 50.
In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.
IT companies on an average returned 85% of profits to shareholders via dividends or buybacks, with less than 15% reinvested in capacities and capabilities; the case is almost inverse for pharma firms.
The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.
Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent
Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.
Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country
In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.
Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.
At 01:13 PM on Tuesday; Nifty Pharma index, the top gainer among sectoral indices, was up 0.2 per cent, as compared to 1.1 per cent decline in the Nifty 50.
Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.
According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,
Systematix said the recent US FDA approval of Zycubo, a Menkes disease treatment marketed by Sentynl Therapeutics, significantly enhances the company's growth outlook
Gland Pharma jumped 4.80 per cent to ₹1,790.40, the highest level since December 3, 2025, on the National Stock Exchange.